A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia.
Ji Bak KimWoo Hyuk SongJong Sung ParkTae-Jin YounYong Hyun ParkShin-Jae KimSung Gyun AhnJoon-Hyung DohYun-Hyeong ChoJin Won KimPublished in: PloS one (2021)
In high-risk Asian patients with hypercholesterolemia, atorvastatin 20 mg was both efficacious in reducing LDL-C and cost-effective compared with atorvastatin 10 mg.